Preimplantation Genetic Testing for Aneuploidy of Polar Bodies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-20

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study intends to randomly group the patients with advanced maternal age and poor ovarian response, and the study group will undergo polar body biopsy, and the next-generation sequencing(NGS) technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores. In the control group undergo routine culture and the transfer priority is determined according to the morphological score only. The transfer of frozen embryos at the cleavage or blastocyst stage was permitted. Cumulative live birth rate, miscarriage rate and time required to obtain a live birth up to two ovulatory cycles in a year.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Blastocyst Euploidy Assessment and Conditioned embryO traNsfer

NCT02353364

Infertility

UNKNOWN PHASE1

Embryo Selection by Noninvasive Preimplantation Genetic Test

NCT04339166

Infertility Chromosome Abnormality

COMPLETED NA

Clinical Application of Non-invasive PGT-A

NCT04856696

Genetic Testing

COMPLETED NA

Preimplantation Genetic Screening in Women of Advanced Maternal Age

NCT00795795

Chromosomal Abnormalities

COMPLETED NA

PGT-A Versus Blastocyst Morphology Selection

NCT03095053

Pregnancy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Subfertility

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Polar body biopsy group

The study group will undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.

Group Type EXPERIMENTAL

polar body biopsy

Intervention Type PROCEDURE

Undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.

Control group

The control group will undergo routine culture and the transfer priority is determined according to the morphological score only.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

polar body biopsy

Undergo polar body biopsy, and the NGS technology will be used to evaluate the polar body euploidy and then predict the euploidy of the oocyte. Embryo transfer priority according to the NGS test results and morphological scores.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients between their 36th and 42st birthdays;
* absence of any type of genetic abnormality in the patient's personal and family history;
* MⅡ oocytes: 2-9 .

Exclusion Criteria

* treatment involving donor oocytes;
* any type of genetic abnormality or family history of genetic abnormality in subject or partner;
* with assisted reproductive technology and pregnancy contraindications and with diseases that have a definite effect on pregnancy;
* poor embryo quality in previous cycles;
* Preimplantation genetic testing for aneuploidy(PGT-A) cycles;
* MⅡ oocytes ≥10 or ≤ 1;
* three or more previous failed IVF or Intracytoplasmic sperm injection(ICSI) cycles.

Minimum Eligible Age

36 Years

Maximum Eligible Age

42 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes